This presentation is on the medications semaglutide and tirzepatide , prescribed under brand names such as Ozempic, Wegovy and Monjaro, and others, some of which are in development. These drugs are GLP-1 agonist medications most commonly used for the treatment of type 2 diabetes, but more recently it’s been in the spotlight as a medication for weight loss, causing controversy, misunderstanding, questions and significant shortages of the medication.

Dr. DeSarbo will briefly look at these medications from all perspectives including their use in diabetes, as a weight loss drug for the medical definition of obesity, and their potential impact and fallout with the eating disorder population.